Perspective Therapeutics, Inc. (NYSE:CATX) Receives $14.44 Consensus Target Price from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been given a consensus rating of “Buy” by the twelve research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $14.44.

CATX has been the topic of several research analyst reports. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. Scotiabank initiated coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research note on Monday, March 31st.

Insiders Place Their Bets

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 38,145 shares of the business’s stock in a transaction on Monday, March 31st. The stock was purchased at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the purchase, the director now directly owns 108,982 shares of the company’s stock, valued at approximately $233,221.48. This trade represents a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Juan Graham bought 33,333 shares of the firm’s stock in a transaction on Friday, March 28th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the transaction, the chief financial officer now owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. The trade was a 1,649.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 115,696 shares of company stock worth $256,344 in the last quarter. Corporate insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CATX. FMR LLC lifted its holdings in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. Janus Henderson Group PLC lifted its stake in Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares in the last quarter. Deerfield Management Company L.P. Series C grew its position in Perspective Therapeutics by 4.3% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock worth $9,375,000 after purchasing an additional 120,991 shares in the last quarter. Octagon Capital Advisors LP increased its position in shares of Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after acquiring an additional 882,528 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 8.2 %

CATX stock opened at $1.80 on Friday. The business’s 50 day moving average is $2.77 and its 200-day moving average is $5.86. Perspective Therapeutics has a 1-year low of $1.79 and a 1-year high of $19.05.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.